Thornburg Investment Management Inc. Acquires 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Thornburg Investment Management Inc. raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 91.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,004 shares of the company’s stock after buying an additional 28,124 shares during the period. Thornburg Investment Management Inc. owned 0.09% of Vera Therapeutics worth $2,495,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. SG Americas Securities LLC raised its stake in shares of Vera Therapeutics by 116.7% in the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock valued at $857,000 after acquiring an additional 10,916 shares in the last quarter. Barclays PLC raised its position in shares of Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock valued at $3,774,000 after purchasing an additional 41,394 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Vera Therapeutics in the fourth quarter worth $2,948,000. Victory Capital Management Inc. boosted its holdings in shares of Vera Therapeutics by 515.0% during the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company’s stock worth $9,949,000 after buying an additional 197,014 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in Vera Therapeutics by 44.2% in the 4th quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company’s stock worth $544,000 after acquiring an additional 3,942 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $21.25 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a 50-day moving average of $23.49 and a 200-day moving average of $33.91. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.14 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. As a group, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Guggenheim raised their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. JPMorgan Chase & Co. dropped their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. HC Wainwright started coverage on Vera Therapeutics in a research report on Monday, May 5th. They issued a “buy” rating and a $75.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. Finally, Cantor Fitzgerald reduced their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $63.33.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.